Skip to main content
Premium Trial:

Request an Annual Quote

Ford Kennedy, John Josef Molenda, Alan D. Lourie

Premium
ITI Life Sciences, a Scottish entrepreneurial innovation fund, last week said that it has appointed Ford Kennedy as director of commercialization.
 
Kennedy’s role at ITI Life Sciences is to identify commercial opportunities and secure licenses for its portfolio of new technologies and intellectual property resulting from ITI research programs. Most recently, he served as director of scientific sourcing and new technologies at Millipore.
 

 
John Josef Molenda has joined Jenner & Block's New York office as of counsel in the firm's intellectual property and appellate and supreme court practices.
 
Most recently, Molenda was an associate at Frommer Lawrence & Haug LLP, where he concentrated his practice in chemical, pharmaceutical, and biotech patent litigation.
 
Molenda has a PhD in chemistry from Vanderbilt University, and conducted post-doctoral research in DNA topology at New York University. He holds a JD from the University of Michigan, and served as a judicial law clerk to the Honorable Alan D. Lourie, United States Court of Appeals for the Federal Circuit, from 1998 to 2000.
 

Molenda has litigation experience in a wide range of technologies, including drug development, genetic engineering, biochemistry, chemical compositions and material science, Jenner & Block said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more